| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-200201150-00002 |
| P698 | PubMed publication ID | 11792970 |
| P2093 | author name string | Constanze Schönemann | |
| Gerhard Opelz | |||
| Bernd Döhler | |||
| Caner Süsal | |||
| Manfred Wiesel | |||
| Peter Schnülle | |||
| Steffen Pelzl | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3-6 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Soluble CD30 as a predictor of kidney graft outcome | |
| P478 | volume | 73 |
| Q42878989 | A clinical scoring system highly predictive of long-term kidney graft survival |
| Q35687821 | Advances in pre- and posttransplant immunologic testing in kidney transplantation |
| Q46246128 | Association between serum soluble CD30 and serum creatinine before and after renal transplantation. |
| Q46095776 | Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy. |
| Q39384930 | Biomarkers to detect rejection after kidney transplantation. |
| Q79150247 | CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response |
| Q47778046 | CD4-veCD8-ve CD30+ve T cells are detectable in human lung transplant patients and their proportion of the lymphocyte population after in vitro stimulation with donor spleen cells correlates with preservation of lung physiology |
| Q83061041 | Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA |
| Q37685073 | Detecting adaptive immunity: applications in transplantation monitoring |
| Q51874065 | Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation? |
| Q37196119 | Five-year clinical effects of donor bone marrow cells infusions in kidney allograft recipients: improved graft function and higher graft survival |
| Q81482579 | High pretransplantation soluble CD30 levels: impact in renal transplantation |
| Q79439010 | High serum soluble CD30 does not predict acute rejection in liver transplant patients |
| Q37418386 | Histocompatibility methods. |
| Q42281533 | Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy |
| Q64053693 | Immunological Alterations due to Hemodialysis Might Interfere with Early Complications in Renal Transplantation |
| Q73573505 | Interleukin-6, interleukin-8, and interleukin-10 in kidney transplantation: improved risk strategy? |
| Q40401634 | Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes |
| Q38773711 | Moving Biomarkers toward Clinical Implementation in Kidney Transplantation |
| Q26765345 | Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination |
| Q41037053 | Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients' Survival |
| Q43272944 | Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study |
| Q85224322 | Post-transplant monitoring of soluble CD30 level as predictor of graft outcome: a single center experience from China |
| Q86779666 | Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation |
| Q43791140 | Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection |
| Q46163952 | Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection |
| Q44215754 | Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation |
| Q83344990 | Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30 |
| Q47335081 | Pretransplant soluble CD30 serum concentration does not affect kidney graft outcomes 3 years after transplantation |
| Q36176628 | Prognostic assays for rejection and tolerance in organ transplantation |
| Q84132184 | Serial soluble CD30 measurements as a predictor of kidney graft outcome |
| Q42987413 | Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation. |
| Q43466537 | Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft |
| Q79911171 | Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies |
| Q86104164 | Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation |
| Q80512157 | Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft |
| Q34639457 | Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients |
| Q79208821 | Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30 |
| Q43274504 | TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion. |
| Q53526089 | Value of soluble CD30 in liver transplantation. |
Search more.